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OBJECTIVES The aim of this study was to evaluate the consequences, measured as mortality and in-hospital
stroke, of the use of thrombolytic therapy among patients with acute myocardial infarction
(AMI), who do not fulfill accepted criteria or who have contraindications to thrombolytic
therapy (i.e., overutilization) and among patients who are withheld thrombolytic treatment
despite fulfilling indications and having no contraindications (i.e., underutilization).
BACKGROUND The implementation of treatment with thrombolysis in clinical practice is not in accordance
with the accepted criteria from randomized studies. The consequence has been over- and
underutilization of thrombolytic therapy among patients with AMI in clinical practice. The
outcome of overutilization of thrombolytic therapy has not been described previously.
METHODS We examined 6,676 consecutive patients admitted to the hospital with an AMI and recorded
characteristics, in-hospital complications and long-term mortality.
RESULTS Overall, 41% of the patients received thrombolytic therapy. Thrombolytic therapy was
underutilized in 14.3% and overutilized in 12.9% of the patients. The use of thrombolytic
therapy was associated with reduced mortality in every subgroup examined, including patients
without an accepted indication, with an accepted indication and in patients with prior stroke.
The risk ratio of in-hospital stroke was not increased in connection with thrombolytic
therapy, not even in patients with prior stroke (relative risk 5 0.237, 95% confidence interval:
0.031 to 1.810, p 5 0.17).
CONCLUSIONS With the large benefit known to be associated with thrombolytic therapy and the favorable
result of thrombolytic therapy in patients with contraindications observed in this study, we
conclude that a formal evaluation of thrombolytic therapy in wider patient categories is
warranted. (J Am Coll Cardiol 2001;37:1581–7) © 2001 by the American College of
Cardiology
Intravenous thrombolytic therapy has received worldwide
acceptance as one of the cornerstones in the treatment of
patients with acute myocardial infarction (AMI). In ran-
domized studies, thrombolytic therapy alone is shown to
reduce mortality by approximately 25% and combined with
aspirin is shown to reduce mortality by 42% (1).
See page 1588
There is a consensus that patients presenting within 12 h
of onset of symptoms with ST-segment elevation or bundle
branch block (2) will benefit from thrombolytic therapy and
that patients not fulfilling these criteria may even be harmed
by the treatment. A substantial number of patients who
fulfill the accepted indications do not receive the treatment
due to contraindications. The contraindications originate
from clinical trials that established the therapy and where
safety was of primary concern. The rationale for the con-
traindications was based on controversial evidence, empiri-
cism, rational considerations and experience, but not on
earlier clinical trials. Nonetheless, the contraindications are
accepted by official guidelines (3,4).
In this situation, clinical practice will necessarily demon-
strate the appropriate use, underutilization and overutiliza-
tion of thrombolytic therapy. Underutilization has received
much attention (5–7), but the consequences of giving
thrombolytic therapy to patients who either do not fulfill
accepted indications or who have accepted contraindications
have not received attention. We have, therefore, found it
important to perform a comprehensive comparison of the
consequences of underutilization and overutilization of
thrombolytic therapy in a large series of consecutive patients
admitted to the hospital alive with an AMI. The analyses
will focus on survival and in-hospital stroke.
METHODS
Patients. The study population consisted of consecutive
patients over 18 years old and admitted with an AMI to one
of 27 Danish coronary care units from 1990 to 1992. All
study departments had complete regional uptake. The
presence of an AMI required chest discomfort or electro-
cardiographic changes suggestive of infarction or ischemia
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and was accompanied by an increase in cardiac enzymes to
twice the upper normal value of the local hospital laboratory.
Data were collected prospectively as part of the screening
procedure for the TRAndolapril Cardiac Evaluation study
(TRACE) (8), which was approved by the regional ethical
committees of Denmark.
A medical history was obtained for every patient, and an
echocardiography was recorded on videotape for evaluation
of left ventricular systolic function, estimated as wall motion
index. In-hospital complications, including stroke and sur-
vival, were systematically recorded for all patients.
Data concerning electrocardiograms (ECG) were col-
lected by the study personnel as a summary of ECG on days
1 to 3. ST-segment elevations were defined as at least one or
more ST-segment elevations of 2 mm in chest leads or
1 mm in limb leads. ST-segment depressions were defined
as at least one or more ST-segment depressions of 1 mm in
chest or limb leads.
Thrombolytic therapy. No strict criteria for thrombolytic
therapy were applied at the time of this study. Treatment
with thrombolytic therapy was left to the judgment of the
attending physician. The following indications were used, in
general: admission ,12 to 24 h from onset of symptoms
consistent with AMI and new changes in the ECG (ST-
segment elevation or bundle branch block). ST-segment
depression or T-wave inversions represented relative crite-
ria. Retrospectively, indications were categorized according
to the recommendations given by the Fibrinolytic Therapy
Trialist Collaborative Group (FTT). Indications for treat-
ment with thrombolysis were admission within 12 h of
onset of relevant clinical symptoms and ECG changes
consisting of pathological ST-segment elevation or bundle
branch block. Patients not having indications were marked
as having “no indications.”
Conditions considered as contraindications were gastro-
intestinal ulcer, known anemia, pregnancy, malignant neo-
plasm or “other risk of bleeding” (i.e., known aortic aneu-
rysm, recent operation or trauma, hemorrhagic diathesis and
ongoing anticoagulation treatment), history of stroke and
severe uncontrolled hypertension.
Mortality. Mortality status of all patients was obtained on
June 26, 1998. Survival data of 39 patients could not be
obtained after discharge.
Statistical analysis. All tests of statistical significance were
two-tailed, and p values of ,0.05 were considered signifi-
cant. Logistic multivariate regression analyses were per-
formed to examine the association between baseline char-
acteristics and risk of stroke or death at day 30 using
backward selection procedure. Long-term mortality was
examined using Cox proportional hazard regression analy-
sis. All analyses were performed with SAS statistical pack-
age programs (Version 6.12, SAS Institute, Cary, North
Carolina).
RESULTS
The study population consisted of 6,676 consecutive pa-
tients admitted to the hospital with an enzymatic-verified
AMI. Due to missing data concerning thrombolytic ther-
apy, 84 (1.3%) patients were excluded, leaving 6,592 pa-
tients for analyses. Figure 1 illustrates a chart classifying the
patients according to indications and contraindications for
thrombolytic therapy and treatment with thrombolysis.
A total of 2,690 patients (40.8%) received thrombolytic
therapy. Baseline characteristics according to indications for
thrombolytic therapy or the presence of contraindications
are listed in Table 1. The fibrinolytic agents used were
streptokinase for 2,563 (95.3%) patients, alteplase for 89
(3.3%), while 38 (1.4%) patients received other fibrinolytic
drugs.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ECG 5 electrocardiogram
FTT 5 Fibrinolytic Therapy Trialist Collaborative
Group
TRACE 5 TRAndolapril Cardiac Evaluation study
Figure 1. Flowchart of 6,676 consecutive patients with acute myocardial infarction screened for the TRAndolapril Cardiac Evaluation (TRACE) study.
The chart is divided according to indications, contraindications and use of thrombolytic therapy.
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Underutilization of thrombolytic therapy. An indication
for thrombolytic therapy was present for 2,781 patients
(42.2%) who were registered as having “no contraindica-
tions.” Of these patients, 1,839 (66.1%) received thrombo-
lytic therapy (Table 2). Therefore, thrombolytic therapy was
underutilized in 942 cases.
Overutilization of thrombolytic therapy. There were
3,811 (57.8%) patients who were registered as having “no
indications” or at least one contraindication for the use of
thrombolytic therapy. Of these patients, 851 received
thrombolytic therapy. Thrombolytic therapy was, thus,
overutilized in 851 patients. In principle, the 3,811 patients
with “no indications,” or at least one contraindication for
the use of thrombolytic therapy, can be divided into three
group with dissimilar reasons for not receiving thrombolytic
therapy: 1) 2,777 patients had “no indications”, 2) 414
patients had contraindications, and 3) 620 patients had “no
indications” as well as at least one contraindication (Fig. 1).
The most common reason for “no indication” was hospital
admission later than 12 h after onset of symptoms, explain-
ing 60.9% of such classifications. There were 1,850 patients
(54.5%) who had no ST-segment elevations or bundle
branch block, and symptoms were not consistent with
infarction in 814 patients (24.0%).
Contraindications were infrequent (16%), but 20.9% of
the patients with at least one contraindication were treated
with thrombolysis. The most common reason for contrain-
dication was a history of prior stroke, which was present in
540 (52.2%) patients, and the other reasons for contraindi-
cation were that 20.3% of the patients had cancer, 17.8%
gastrointestinal ulcer, 9.1% were on anticoagulation treat-
ment, 7.1% had high risk of bleeding and 4.8% had known
anemia. There were 101 patients who had two contraindi-
cations, and eight patients had three contraindications. No
cases of uncontrolled hypertension were registered.
Patients with prior stroke are assumed to have an exces-
sive high risk of an in-hospital stroke in connection with
thrombolytic therapy. Of 540 patients with prior stroke, 99
(18.3%) received thrombolytic therapy (Table 2).
Thrombolytic therapy and mortality. The odds ratio of
mortality associated with thrombolytic therapy in univariate
analysis was 0.502 (95% confidence interval: 0.466 to 0.540,
p , 0.0001). Thirty-day mortality for patients receiving
thrombolytic therapy versus those not treated was 7.9% and
15.9% (Fig. 2). Mortality of patients who received throm-
bolytic therapy and had no contraindication was 7.7%, while
the mortality was 10.6% for those who received thrombo-
lytic therapy despite contraindications (p 5 0.12).
The independent relative risk of mortality at 30 days and
four years was addressed in a multivariate Cox regression
model with backward selection (Table 3). Parameters for
the logistic regression analysis were chosen on the grounds
of being of clinical importance or statistically significant in
univariate analysis. Twenty-nine parameters were included
Table 1. Baseline Characteristics Among All Patients and Relevant Subgroups With Acute Myocardial Infarction
All (%)
n 5 6,592
Fulfilling Standard
Criteria Without
Contraindications (%)
n 5 2,781
Not Fulfilling
Indications (%)
n 5 3,397
Having
Contraindications (%)
n 5 1,034
Prior Stroke
(%) n 5 540
Age, in years (median [95% CI]) 68.6 (46.7–84.1) 66.7 (45.3–82.6) 69.7 (47.3–84.8) 72.6 (53.9–84.7) 73.6 (54.5–85.3)
Male gender 67.5 70.6 65.3 63.2 62.6
Thrombolysis 40.8 66.1 20.6 20.9 18.3
Prior AMI 23.5 20.0 26.1 28.6 30.9
Anterior AMI 26.5 34.3 19.4 22.2 22.1
BBB 8.1 8.9 6.9 11.5 14.0
ST-elevations 64.3 91.1 39.3 54.5 53.3
ST-depression without elevations 16.2 — 31.6 21.2 21.8
Chest pain on admission 88.3 — 77.2 81.5 79.4
Prior stroke 8.2 — 9.6 52.2 100
Diabetes mellitus 10.9 9.5 11.8 13.2 17.6
Hypertension 22.6 19.7 24.1 29.3 35.1
Angina pectoris 36.8 32.6 39.5 43.1 44.6
Congestive heart failure 17.0 11.6 20.7 27.2 30.1
Smoking 51.5 56.1 47.6 49.0 29.1
Atrial fibrillation 3.9 2.6 4.8 8.1 9.8
Delay, in hours (median [95% CI]) 3.1 (0.5–39.4) 2.4 (0.6–8.8) 5.8 (0.3–5.9) 3.3 (0.6–36) 3 (0.4–35.5)
BMI (median [95% CI]) 25.4 (19.5–32.5) 25.6 (20.1–32.6) 25.3 (19.1–32.4) 24.7 (18.4–32.3) 24.7 (18.7–32.0)
Weight (median [95% CI]) 75 (52–98) 75 (54–98) 74 (50–98) 72 (49–95) 71 (49.1–93)
Anticoagulation therapy 1.4 — 1.8 9.1 6.1
Anemia 0.8 — 1.0 4.8 1.5
Gastrointestinal ulcer 2.8 — 3.1 17.8 3.3
Cancer 3.2 — 3.6 20.3 5.0
Risk of bleeding 1.1 — 1.4 7.1 0.9
30-day mortality 12.6 10.8 13.4 19.8 23.5
In-hospital stroke 1.3 0.7 1.8 2.5 3.7
AMI 5 acute myocardial infarction; BBB 5 bundle branch block; BMI 5 body mass index; CI 5 confidence interval; ECG 5 electrocardiogram; MI 5 myocardial infarction;
WMI 5 wall motion index.
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in the logistic regression analysis: age, gender, hypertension,
diabetes mellitus, atrial fibrillation, thrombolytic therapy,
time from onset of symptoms until admission, Killip class
$3, risk of bleeding (i.e., known aortic aneurysm, recent
operation or trauma, hemorrhagic diathesis and ongoing
anticoagulation treatment), chest pain on admission, ST-
segment depression, ST-segment elevations without depres-
sion, bundle branch block, anemia, cancer, use of medica-
tion for gastrointestinal ulcer, current smoker, body mass
index, anterior Q-wave infarction, time of day, wall motion
Table 2. Baseline Characteristics Among 2,781 Patients With AMI Fulfilling Standard Criteria for Thrombolytic Therapy Without
Contraindications and 540 Patients With Prior Stroke According to Patients Receiving Treatment With Thrombolytic Therapy
Standard Indications History of Prior Stroke
Thrombolysis Thrombolysis
Yes (n 5 1,839) No (n 5 942) Yes (n 5 99) No (n 5 441)
Age, in years (median [95% CI]) 64.4 (44.7–79.2) 71.8 (48.5–85.7) 68.2 (50.7–79.6) 74.4 (56.3–85.7)
Male gender 74.2 63.6 76.8 59.4
Prior AMI 16.2 27.5 20.4 33.2
Anterior AMI 35.9 31.1 28.6 20.7
BBB 4.5 16.8 4.0 16.2
ST-elevations 95.2 83.2 82.8 46.8
ST-depression without elevations — — 10.1 24.4
Chest pain on admission 100 100 93.8 76.2
Aspirin on admission 90.2 61.5 82.8 46.9
Diabetes mellitus 7.4 13.6 12.1 18.8
Hypertension 18.1 23.0 38.4 34.3
Angina pectoris 27.6 42.5 40.4 45.6
Congestive heart failure 7.0 20.6 13.1 33.9
WMI (median [95% CI]) 1.4 (0.8–2.0) 1.3 (0.7–2.0) 1.3 (0.9–2.0) 1.2 (0.6–2.0)
Smoking 61.8 44.7 53.1 39.9
Atrial fibrillation 1.6 4.6 5.1 10.9
Gastrointestinal ulcer — — 1.0 3.9
Delay in hours (median [95% CI]) 2.1 (0.5–7.8) 3.2 (0.8–10.3) 2.3 (0.3–6.8) 3.5 (0.5–40.5)
BMI (median [95% CI]) 25.6 (20.2–32.7) 25.4 (19.6–32.7) 25.1 (20.4–30.8) 4.5 (18.3–32.0)
Weight (median [95% CI]) 75 (55–98) 74 (52–97) 73 (57–93) 70 (48–93)
Anticoagulation — — — 7.5
Anemia — — 1.0 1.6
Cancer — — 4.0 5.2
Risk of bleeding — — 2.0 0.7
30-day mortality 7.8 16.5 14.1 25.6
In-hospital stroke 0.7 0.8 2.0 4.1
AMI 5 acute myocardial infarction; BBB 5 bundle branch block; BMI 5 body mass index; CI 5 confidence interval; ECG 5 electrocardiogram; WMI 5 wall motion index.
Figure 2. Mortality with 95% confidence limits according to whether (hatched) or not (solid) the patients received thrombolytic therapy.
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index, congestive heart failure, ventricular fibrillation, ven-
tricular tachycardia, weight, history of stroke, AMI, angina
pectoris or gastrointestinal ulcer.
The analyses were performed in subgroups, and throm-
bolytic therapy was associated with a favorable outcome,
both short- and long-term. In the subgroups where throm-
bolytic therapy was underutilized, 30-day and four-year
mortality was 16.3% and 45.6%, respectively. Among pa-
tients where thrombolytic therapy was overutilized, 30-day
and four-year mortality were 8.1% and 30.0%, respectively.
In-hospital stroke in relation to thrombolytic therapy.
The in-hospital incidence of stroke among patients treated
with thrombolytic therapy versus those not treated was 0.7%
and 1.7%, respectively (p 5 0.001). In-hospital stroke
among patients where thrombolytic therapy was overutilized
was 1.0% versus 1.7% for patients not treated (p 5 0.26).
Among patients where thrombolytic therapy was underuti-
lized, the risk of stroke was 0.8% versus 1.0% when
thrombolytic therapy was overutilized (p 5 0.65).
Patients with a history of prior stroke had an in-hospital
stroke incidence of 2.0% when thrombolytic therapy was
used and 4.1% when thrombolytic therapy was not used
(p 5 0.49). Importantly, patients who received thrombolytic
therapy had a more favorable risk profile (Table 2).
The independent risk ratio of in-hospital stroke in
association with thrombolytic therapy was addressed in
multivariate Cox regression models with backward elimina-
tion (Table 4); characteristics included are listed in Throm-
bolytic therapy and mortality section. There was no sub-
group among which thrombolytic therapy was associated
Table 3. Multiple Logistic Regression Models With Backward Selection for Predicting the Risk Ratio of Death at 30 Days and
Four Years With Emphasis on Thrombolytic Therapy
Patient Group Analyzed n
30-Day
Mortality Risk Ratio and
95% CI for
Thrombolytic
Therapy
4-Year
Mortality Risk Ratio and
95% CI for
Thrombolytic
Therapy
Thrombolysis Thrombolysis
Yes No Yes No
All 6,592 7.8 15.8 0.717 (0.568–0.905) 27.1 48.9 0.643 (0.562–0.736)
Not fulfilling standard criteria,
without contraindications
2,765 7.3 13.1 0.618 (0.418–0.911) 27.4 44.5 0.635 (0.502–0.803)
Fulfilling standard criteria without
contraindications
2,769 7.6 16.3 0.903 (0.650–1.254) 25.8 45.6 0.740 (0.601–0.912)
Having at least one
contraindication
1,032 10.7 22.2 0.541 (0.316–0.928) 37.5 64.5 0.477 (0.328–0.694)
Prior stroke 540 14.1 25.6 0.536 (0.283–1.013) 46.5 68.7 0.691 (0.416–1.148)
Prior stroke but otherwise fulfilling
standard criteria for
thrombolytic therapy
182 12.2 32.4 0.289 (0.125–0.667) 43.3 71.8 0.396 (0.206–0.760)
CI 5 confidence intervals.
Table 4. Multiple Logistic Regressions With Backward Selection Model for Predicting the Risk of In-hospital Stroke With Emphasis
on Thrombolytic Therapy
Patient Group Analyzed n
Parameters With
Independent Influence
on In-Hospital Stroke
Risk Ratio and 95% CI
of In-Hospital Stroke for
Thrombolytic Therapy
p Value
Thrombolytic
Therapy
All 6,592 Prior stroke, age, gender,
delay until admission,
congestive heart failure
0.889 (0.495–1.599) 0.69
Not fulfilling standard criteria, but with
no contraindications
2,777 Age, wall motion index 0.637 (0.243–1.666) 0.36
Fulfilling standard criteria without
contraindications
2,781 Killip class $3, age 1.840 (0.663–5.104) 0.24
Having at least one contraindication 1,034 — 0.308 (0.072–1.312) 0.11
Prior stroke 540 Body mass index 0.237 (0.031–1.810 0.17
Prior stroke without any other
contraindication for thrombolytic therapy
456 ST-segment elevations,
bundle branch block,
atrial fibrillation,
congestive heart failure
0.275 (0.036–2.116) 0.21
Prior stroke but otherwise fulfilling standard
criteria for thrombolytic therapy
182 — 0.417 (0.046–3.807) 0.44
Age #60 yr 1,712 Gender 0.236 (0.049–1.143) 0.07
Age .60 yr and #75 yr 3,031 Angina pectoris,
congestive heart failure
0.740 (0.347–1.580) 0.44
Age .75 yr 1,849 Age, gender, weight 0.547 (0.224–1.334) 0.18
CI 5 confidence intervals.
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with a significant excess risk of developing an in-hospital
stroke.
DISCUSSION
To our knowledge, this is the first study that addresses
the consequences of overutilization of thrombolytic therapy
in clinical practice. The study demonstrated that thrombo-
lytic therapy was associated with a reduced risk of mortality
without increasing the risk of stroke in patients either
without standard indications or with accepted contraindi-
cations. Specifically, the risk of in-hospital stroke did not
appear to be increased even in patients with a history of
prior stroke.
Incidence of stroke associated with use of thrombolytic
therapy. The findings we present are in line with a study
from two nationwide surveys suggesting that patients with
AMI and prior cerebrovascular events had adverse outcome
with thrombolytic therapy due to older age and less favor-
able risk profiles, whereas thrombolytic therapy might be
beneficial in selected patients with AMI and nonrecent
prior cerebrovascular event (9). Even an increase in the
incidence of nonfatal intracranial hemorrhage can be justi-
fied from a decision model derived from pooling of ran-
domized trials of intravenous streptokinase. It is stated that
an achieved mortality reduction by thrombolytic therapy can
justify a higher rate of nonfatal intracranial hemorrhage
(10). Among our patients treated with thrombolytic ther-
apy, 0.8% had an in-hospital stroke as compared with 1.7%
among those not treated with thrombolytic therapy. Com-
parable to our data are observations from the National
Registry of Myocardial Infarction (11) where a stroke
frequency of 0.9% among patients who received thrombol-
ysis was found. In Gruppo Italiano per lo Studio della
Sopravvivenza nell’Infarto Miocardico-2 (12) and the
Global Use of Strategies to Open Occluded Coronary
Arteries-I study (13), 1.1% and 1.4% of the patients treated
with thrombolysis had an in-hospital stroke, respectively.
Thus, it is rather reassuring that the implementation of
thrombolytic therapy in clinical practice has not resulted in
an increased incidence of in-hospital strokes, despite the
substantial use of the treatment among patients with con-
traindications.
Selecting for thrombolytic therapy and mortality. In our
population, 40.8% received thrombolytic therapy, but as
many as 34% of patients with AMI did not receive throm-
bolysis, even though indications for treatment with throm-
bolytics were fulfilled. In a recent European study, the
corresponding figure was 20% (14). Numerous other studies
have, in agreement, shown that only 33% to 50% (5,15) of
patients eligible for thrombolytic therapy do receive the
treatment. The 35-day mortality among all our patients
treated with thrombolysis was 8.2%. Among patients who
fulfilled standard indications without contraindications, the
35-day mortality was 8.1%. This is comparable to the
35-day mortality of 9.6% in the thrombolytic studies ac-
cording to FTT. The corresponding mortality among (2)
patients belonging to the group with “indications” who were
not treated with thrombolytic therapy was 18.2%.
Conclusions. In general, mortality among patients with
AMI who do not receive thrombolytic therapy is twice as
high as it is among patients treated with thrombolytic
therapy (16,17); in clinical practice, this is partly due to
selection bias. It is tempting to use the results we have
presented to conclude that contraindications and lack of
indications should be ignored and that thrombolytic therapy
should be given to many more patients. But the correct
conclusion is that physicians are able to select those patients
who are beyond the standard indications but who will
benefit from thrombolytic therapy. Whether thrombolytic
therapy, in general, will benefit part of the rejected high-risk
population remains to be shown.
Perspective. With the large benefit known to be associated
with thrombolytic therapy and the favorable result of
thrombolytic therapy in patients with contraindications
observed in this and other studies, a randomized study of
thrombolytic therapy among patients with some of the
current contraindications is warranted, in particular, in
patients with a risk of bleeding based on events some time
in the past. The benefits of thrombolysis could very well
outweigh the risks in many patients with a risk of bleeding
or stroke.
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